Taejon, South Korea

Jeong Hee Son

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Korea Research Institute of Bioscience and Biotechnology. Active years: 2011.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jeong Hee Son: Innovator in Protein Crystallization

Introduction

Jeong Hee Son is a notable inventor based in Taejeon-si, South Korea. He has made significant contributions to the field of bioscience, particularly in the study of proteins. His work focuses on the crystallization of specific proteins that have implications in cancer research.

Latest Patents

Jeong Hee Son holds a patent for a crystal of a phosphatase of regenerating liver 1 (PRL-1) polypeptide and the method of crystallization thereof. The patent describes the crystal structure of the PRL-1 protein, which features a tertiary structure with five strands of beta-sheet surrounded by six alpha-helices. The well-arranged active site with a closed P-loop allows for the formation of trimers through the farnesylation site at the C-terminus of the protein. This structure is crucial for achieving intracellular migration and membrane localization. The invention is particularly valuable for developing agents that inhibit carcinogenesis and metastasis in cancer.

Career Highlights

Jeong Hee Son is affiliated with the Korea Research Institute of Bioscience and Biotechnology. His research has contributed to advancements in understanding protein structures and their functions, which are essential for therapeutic developments.

Collaborations

Jeong Hee Son has collaborated with notable colleagues, including Seong Eon Ryu and Dae Gwin Jeong. Their combined expertise enhances the research efforts in the field of bioscience.

Conclusion

Jeong Hee Son's innovative work in protein crystallization represents a significant advancement in cancer research. His contributions are paving the way for future developments in therapeutic agents targeting cancer.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…